(Q51123060)

30 March 2018

title

Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. (English)

1 reference

30 March 2018

1 reference

1 reference

1 reference

Bernd Brüggenjürgen

1

1 reference

30 March 2018

Thomas Reinhold

2

1 reference

30 March 2018

Randolf Brehler

3

1 reference

30 March 2018

Eckard Laake

4

1 reference

30 March 2018

Günther Wiese

5

1 reference

30 March 2018

Ulrich Machate

6

1 reference

30 March 2018

Stefan N Willich

7

1 reference

30 March 2018

publication date

1 September 2008

1 reference

30 March 2018

Annals of Allergy, Asthma & Immunology

published in

1 reference

30 March 2018

volume

101

1 reference

30 March 2018

issue

3

1 reference

30 March 2018

page(s)

316-324

1 reference

30 March 2018

Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (I)

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Development of seasonal allergic rhinitis during the first 7 years of life

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Prevalence and rate of diagnosis of allergic rhinitis in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

[A connection between allergic rhinitis and allergic asthma? The "one-airway-one-disease"-hypothesis]

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Complications of allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Specific immunotherapy in rhinitis and asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

[Specific immunotherapy in allergic asthma]

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Remission of allergic rhinitis: An 8-year observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Remission of asthma in the middle aged and elderly: report from the Obstructive Lung Disease in Northern Sweden study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

The connection between allergic rhinitis and bronchial asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single- or double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Cost-effectiveness of grass allergen tablet (GRAZAX) for the prevention of seasonal grass pollen induced rhinoconjunctivitis - a Northern European perspective.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Cost-effectiveness of GRAZAX for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

An introduction to Markov modelling for economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960498-X

7 January 2021

10.1016/S1081-1206(10)60498-X

Identifiers

DOI

1 reference

30 March 2018

1 reference

30 March 2018